DIAGNOS Unveils Private Placement to Fuel Expansion
BROSSARD, Quebec – Diagnos Inc. ("DIAGNOS"), a leader in the early detection of critical health issues, has announced a private placement to secure additional resources for its innovative services. This strategic move, which involves the issuance of 10 units priced at $10,000 each, aims to generate gross proceeds of $100,000.
Details of the Private Placement
Each unit in this private placement comprises two essential elements: an unsecured convertible debenture and stock warrants. The unsecured convertible debenture, valued at $10,000, has a term of 12 months and carries an interest rate of 10%, payable in cash. Holders have the option to convert their principal into common shares at a price of $0.28 each during this term.
Warrant Features
The stock warrants included in each unit allow holders to purchase one share at a price of $0.40 per share, enabling them to benefit from the growth of DIAGNOS.
Use of Proceeds
The funds raised through this private placement will be primarily allocated toward product development and the commercialization of AI-driven screening services. This initiative aligns with DIAGNOS's mission to enhance healthcare delivery through advanced technology.
Management Commitment
Notably, a director of DIAGNOS has committed to subscribe to all units available in this private placement, demonstrating strong insider confidence in the company's direction.
Regulatory Compliance
As part of the issuance process, all securities from this private placement will adhere to a 4-month statutory hold period. Furthermore, the placement is subject to obtaining necessary approvals, including from the TSX Venture Exchange, which ensures compliance with regulatory frameworks.
Insight into DIAGNOS
DIAGNOS is dedicated to utilizing Artificial Intelligence for the early detection of critical eye-related health issues. By employing innovative technologies, the company helps healthcare practitioners improve diagnostic accuracy and streamline workflows, significantly boosting patient outcomes globally. Their commitment to enhancing healthcare services reflects a broader trend towards personalized and efficient medical solutions.
Connect with DIAGNOS
For additional information about DIAGNOS and its cutting-edge approaches to healthcare, interested parties can refer to the company's official website at www.diagnos.com. Furthermore, updates and regulatory documents are available on www.sedarplus.com.
Frequently Asked Questions
What is the purpose of DIAGNOS's private placement?
The private placement aims to raise funds primarily for product development and commercialization of AI-based health screening services.
What are the benefits of the warrants included in the placement?
The warrants allow holders to purchase shares at a predetermined price, providing an opportunity to benefit from potential growth in DIAGNOS's share value.
How are the funds from the placement expected to impact DIAGNOS?
The raised funds are expected to facilitate advancements in technology, improving diagnostic processes and patient outcomes in healthcare.
Who is committed to subscribing to this private placement?
A director of the corporation has committed to subscribe to all units, indicating strong confidence in the company's future direction.
Where can I find more information about DIAGNOS’s health services?
More details can be found on DIAGNOS's website and regulatory filings, which offer insight into their innovative healthcare solutions.
